Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $24,000.

  • Niagen Bioscience's Capital Expenditures fell 41.46% to $24,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $260,000, marking a year-over-year increase of 126.09%. This contributed to the annual value of $163,000 for FY2024, which is 10.14% up from last year.
  • As of Q3 2025, Niagen Bioscience's Capital Expenditures stood at $24,000, which was down 82.22% from $135,000 recorded in Q2 2025.
  • Niagen Bioscience's 5-year Capital Expenditures high stood at $265,000 for Q2 2021, and its period low was $2,000 during Q4 2021.
  • Over the past 3 years, Niagen Bioscience's median Capital Expenditures value was $32,000 (recorded in 2025), while the average stood at $45,636.
  • In the last 5 years, Niagen Bioscience's Capital Expenditures crashed by 99.26% in 2021 and then soared by 8,500.00% in 2022.
  • Quarterly analysis of 5 years shows Niagen Bioscience's Capital Expenditures stood at $2,000 in 2021, then surged by 8,500.00% to $172,000 in 2022, then slumped by 87.79% to $21,000 in 2023, then skyrocketed by 228.57% to $69,000 in 2024, then slumped by 41.46% to $24,000 in 2025.
  • Its last three reported values are $24,000 in Q3 2025, $135,000 for Q2 2025, and $32,000 during Q1 2025.